Skip to main content

Table 1 Frequencies of CTLA-4 polymorphisms in melanoma patients and healthy controls

From: Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

  Controls Melanomas  
  Number (N = 288) % Number (N = 286) % P
AG 49
A/A 152 52.8 132 46.2 0.27
A/G 111 38.5 128 44.8  
G/G 25 8.7 26 9.1  
CT 318
C/C 230 79.9 229 80.1 0.94
C/T 57 19.8 55 19.2  
T/T 1 0.4 2 0.7  
CT 60
A/A 90 31.3 65 22.7 0.071
A/G 135 46.9 151 52.8  
G/G 63 21.9 70 24.5  
JO 27
C/C 90 31.3 73 25.5 0.32
C/T 143 49.7 153 53.5  
T/T 55 19.1 60 21.0  
JO 30
A/A 95 33.0 72 25.2 0.12
A/G 138 47.9 151 52.8  
G/G 55 19.1 63 22.0  
JO 31
T/T 96 33.3 71 24.8 0.047
G/T 144 50.0 151 52.8  
G/G 48 16.8 64 22.4